menu
    • menu
    [{"orgOrder":0,"company":"Enlaza Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Enlaza Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enlaza Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Enlaza Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Enlaza Therapeutics","sponsor":"Avalon GloboCare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Enlaza Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enlaza Therapeutics \/ Avalon GloboCare","highestDevelopmentStatusID":"4","companyTruncated":"Enlaza Therapeutics \/ Avalon GloboCare"}]

    Find Clinical Drug Pipeline Developments & Deals by Enlaza Therapeutics

    Menu

    Enlaza Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enlaza Therapeutics

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed

                            Enlaza Therapeutics

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : J.P. Morgan

                            Deal Size : $100.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Enlaza Raises $100 Million in Series A Financing Led by J.P. Morgan Private Capital

                            Details : The financing will support the further development of Enlaza's proprietary covalent protein technologies and advance their protein drug platform for treating Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 30, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : J.P. Morgan

                            Deal Size : $100.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Enlaza Therapeutics

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed

                            Enlaza Therapeutics

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Avalon GloboCare

                            Deal Size : $61.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Enlaza Therapeutics Launches with $61 Million Financing to Advance the First Covalent Biologic Therapeutic Pla...

                            Details : Enlaza is developing first-in-class covalent protein-based therapeutics to transform the treatment of cancer and other serious diseases. The financing will be used to advance Enlaza’s proprietary War-Lock platform and build a pipeline of covalent biolo...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 15, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Avalon GloboCare

                            Deal Size : $61.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth